Acne Therapeutics Market Report and Forecast 2024-2032

Acne Therapeutics Market Outlook

The acne therapeutics market size was valued at USD 7.7 billion in 2023, driven by the rising emphasis on improving facial aesthetics across the major markets. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032, with the values likely to rise from USD 8.1 billion in 2024 to USD 11.6 billion by 2032.

Acne Therapeutics Market Overview

The prevalence of acne is around 80% in adolescents, however, adult acne is also on the rise, projected to affect nearly 40% of the global population. Around 20% of the acne patients experience moderate to severe acne. While it is not a life-threatening condition, acne comes with psychosocial baggage and may lead to psychological issues such as anxiety, low self-esteem, and even depression. Consequently, the emergence of new treatments with the integration of the latest technologies has become one of the major acne therapeutics market trends in recent years.

Acne therapeutics include topicals and drugs such as hormonal agents or antibiotics. The alternatives vary, based on age, type, and severity of the acne. Therapies like light therapy and chemical peels are also used in some conditions. The acne therapeutics market growth is driven by expediated drug development leading to subsequent growth in FDA approvals. There is an increased focus on offering better therapeutic solutions by merging the latest gene-based therapies with combination therapies.

Increasing Integration of Artificial Intelligence Based Therapeutics

To meet the rising acne therapeutics market demand, there has been growing application of latest technologies such as artificial intelligence to develop dermatology drugs. In November 2023, a biopharmaceutical company, Almirall, with dermatology as a major domain and Absci Corporation, a generative artificial intelligence drug creation company collaborated to offer customized medicines by incorporating AI.

Rising Emphasis on Combating Antibiotic Resistance

Antibiotics for acne treatment have also been a major area of interest amongst researchers. However, broad spectrum antibiotics target both good as well as bad bacteria and antibiotic resistance, which is another key constraint that has emerged in recent years. Therefore, there is ongoing research for effective alternatives leading to substantial growth in the acne therapeutics market share.

A new Yale study, published in March 2023, examined the role of third generation of tetracycline derivative Sarecycline which directly targets Cutibacterium acnes and other gram-positive bacteria, mostly responsible for causing acne. This derivative has gained high prevalence owing to its structural competence over others, which limits the chances of mutation, therefore, opposing antibiotic resistance.

Growth in the Incidence of FDA Approvals to be a Key Driver for Market Demand

The acne therapeutics market growth is driven by increasing drug development activity and marketing authorizations by regulatory bodies. In October 2023, the FDA approved Cabtreo (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%), which is a triple-combination topical treatment for acne. Developed by Bausch Health Companies Inc. and their dermatology business Ortho Dermatologics, this treatment combines the action mechanism of an antibiotic, retinoid and antibacterials. Isotretinoin is another high-dose vitamin A medication that shrinks sebaceous glands along with getting rid of breakout causing bacteria.

In April 2023, Dermata Therapeutics also received a positive response for initiating phase III studies for evaluating their latest once-a-week topical acne treatment DMT310. Derived from naturally sourced freshwater sponge, this drug is also being studied to treat rosacea and psoriasis. To expand their product line, the company is working towards developing a new candidate DMT410, that will employ a needle free intradermal administration of botulinum toxin to treat various aesthetic and medical skin conditions. Consequently, the acne therapeutics market size is expected to grow with ongoing advancements in the pharmaceutical domain.

Acne Therapeutics Market Segmentation

Market Breakup by Injury Type

• Complete Acne Therapeutics

• Incomplete Acne Therapeutics

Market Breakup by Treatment Type

• Therapeutics
  • Retinoid
  • Antibiotics
  • Hormonal Agents
  • Anti-inflammatory
  • Other Agents

• Other Treatments

Market Breakup by Route of Administration

• Oral

• Topical

• Others

Market Breakup by End User

• Hospitals

• Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
• Japan

Acne Therapeutics Market Overview

Acne is the most common skin condition in the United States, affecting approximately 3 million people every year. So, the United States is anticipated to lead the acne therapeutics market share. The emphasis on product line expansion is a vital aspect of the market size. In October 2023, Crown Therapeutics unveiled two new products in their dermatologist backed award winning product line. PanOxyl Clarifying Exfoliant with 2% Salicylic Acid and PanOxyl Adapalene 0.1% Gel are clinically proven to treat acne with their high-performance ingredients.

Europe is another key player of the market with hefty investments occurring in various key conditions. In March 2023, a Swedish pharmaceutical company, Vakona, received USD 13.4 million investment from five investors to develop a new acne treatment drug. In addition, the presence of academic and research institutions is also a key aspect of growing market value.

The Asia Pacific acne therapeutics market value is expected to rise with increasing engagement of government and private sector companies to improve the healthcare infrastructure available in the region. In addition, there are several mergers and acquisitions occurring to offer better treatment alternatives to patients, which is fueling the market growth in the region.

Acne Therapeutics Market: Competitor Landscape

In December 2023, Eligo Bioscience, a gene-editing company, received a USD 30 million Series B funding by Sanofi Ventures for their flagship program EB005. This program is aimed at treating moderate to severe acne vulgaris with the application of in vivo gene-editing techniques. Such investments indicate the growing trend of using novel technologies to address diseases triggered by expression of bacterial genes.

The key features of the acne therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Cipher Pharmaceuticals

• GlaxoSmithKline PLC

• L'Oréal S.A. (La Roche-Posay Laboratoire Dermatologique)

• Teva Pharmaceuticals

• Sun Pharmaceuticals 

• Abbvie Inc.

• F. Hoffmann-la Roche Ltd

• Viatris Inc.

• Johnson & Johnson

• Bausch Health Companies Inc.

• Perricone MD

• Glow Biotics LLC

• Revision Skincare

• The Beauty Health Company

• PHYTOMER

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report